3 results
Primary Objectives:* To compare overall survival (OS) of patients who receive NKTR-102given once every 21 days (q21d) to patients who receive Treatment ofPhysician*s Choice (TPC) selected from the following list of seven singleagentintravenous…
Primary objective:To investigate the safety of turoctocog alfa pegol during continuous use for prevention and treatment of bleeding episodes of previously turoctocog alfa pegol treated severe haemophilia A patients.Secondary objectives:To…
The SPYRAL AFFIRM study will evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in a population of approximately 1300 renal denervation treated subjects with up to 36 months of follow-up, including several sub-…